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You are a NASA flight surgeon working on console at Mission Control during an 
International Space Station (ISS) mission.  You have completed extensive NASA and 
military or civilian aerospace medical training to address almost any anticipated 
medical contingency, and can summon advice from space medicine experts located 
around the world.  Your present duties include providing medical support for two male 
astronauts and one female cosmonaut who are working on the ISS for a planned 6-
month flight. These three highly dedicated and motivated crewmembers underwent 
very rigorous medical examinations at the time of their selection and annually 
thereafter to obtain and maintain medical certification for flight.  You have also 
performed annual and pre-flight medical exams, in-flight periodic health status exams, 
exercise monitoring, private medical conferences, biomedical monitoring during 
spacewalks, and monitoring of vehicle environmental parameters and daily crew 
schedules. 
One of the crewmembers, a 37-year-old Russian female, designated Flight Engineer 2 
(FE2), who has been on orbit for 2 months, has just requested an unscheduled private 
medical conference (PMC) with you, the flight surgeon, via private space-to-ground 
voice loop from the ISS.  The BME, who is the only person on SURGEON console in 
MCC, requests that the private medical conference be relayed to your house by 
phone.  It is 3 AM local time when the phone rings and the BME is on the line stating 
that FE2 has requested an unscheduled PMC.  Because the Russian flight surgeon is 
unavailable at this time, the BME has also arranged for Russian-English translation 
services to be provided in case there is a communication problem with the native 
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 speaking female Russian Soyuz pilot. The Crew Medical Officer (CMO) on the ISS is 
conversant in Russian and has received 40 hours of medical training in areas of 
emergency procedures and general medical procedures.  You release the BME from 
the private communication loop and commence the medical conference with FE2, who 
expresses serious concerns about her lower right quadrant pain which has progressed 
from a 2/10 to 8-9/10 in severity over a 5 hour period.  During the PMC, FE2 denied 
ever having extreme pain like this in the past and states that it is completely 
unbearable and no maneuver, or position improves it.      
You have her complete medical record on a notepad computer at your house and 
quickly review during the conversation that FE2 had a mother who died from colon 
cancer at the age of 56, a father who has a history of multiple episodes of 
nephrolithiasis starting at age 45, which were all treated medically, and a brother who 
has had one episode of diverticulitis.  FE2 weight = 75 Kg, height = 172 cm., is 
premenopasual and married with 2 children (Gravida 2 – Para 2 females ages 9 and 
12 both healthy). FE2 has been in perfect health up to this PMC with no outstanding 
medical issues.  FE 2 consumes a daily calcium pill along with a multivitamin as per 
prescription from the Russian flight surgeon. 
FE2 denies experiencing any shortness of breath, palpitations, fatigue, or weakness 
and symptoms of presyncope.  She denies dysuria, urgency, frequency, vomiting, 
chills shakes, diarrhea, and constipation. She describes her pain as undulating 
cramps and CVA severe pain and is often associated with nausea. She took aspirin 
325mg 10 minutes prior to calling the Flight Surgeon with no noticeable effect on her 
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 pain.  The limited upmass from the recent grounding of the Shuttle fleet has caused 
the crew to conserve water. Upon further questioning, FE2 notes that her busy 
schedule has prevented her from drinking the minimum of 2 liters of fluids you 
recommend the crew to consume daily.   
Question 1. Based on your limited knowledge at this time, your differential diagnosis 
should include which of the following potentially life-threatening causes? 
A. Aortic dissection 
B. Appendicitis 
C. Ruptured Ovarian Cyst 
D. Diverticulitis 
E. Ectopic pregnancy (2 months since launch) 
F. Renal Obstruction 
G. Acute Cholecystitis 
H. Gastritis 
I. Small Bowel Obstruction.  
J. All of the above 
The history of FE2’s pain and the HPI causes you to consider many of the above 
maladies in the differential diagnosis.  You realize that several of these can be ruled 
out with diagnostic imaging.  After the PMC you transfer the control of the private 
voice from the ISS back to the BME and phone the flight director from your car as you 
drive to MCC.  
Question 2. While driving to MCC in your car, you think of additional information that 
should be obtained from the medical record or directly from the patient. What 
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 characteristics in the family or past medical history raise concern with this case 
prompting a more detailed history? 
A. Family history of kidney stones  
B. Diet ( Russian’s diet is rich in meat, a source of uric acid, NaCl, etc) 
C. Preflight Stone Risk Profile  
D. Geographic, environmental conditions 
E. Family history of cholelithiasis  
F. Family history of  peptic ulcer 
G. A history of any diet supplements of Vitamins 
H. Recent or chronic medications 
I. All the above 
After you arrive at MCC, a video PMC is conducted and during the medical 
examination of FE2 by the CMO under your guidance, the following information is 
obtained.13  You provide guidance on how to listen for bowel sounds and the 
technique for palpation and percussion of the abdomen, however this proves to be 
very difficult for a non-physician under microgravity conditions with high ambient noise 
levels in the ISS (65-70 dBA) with a patient is uncooperative due to extreme 
discomfort.   
On examination it is noticed that the patient is very anxious, diaphoretic, writhing in 
pain, and speaking in short sentences. She points to her lower abdomen and right 
costovertebral angle (CVA) as the location of pain.  She cannot get comfortable and 
feels like the pain is “deep inside her”.   She is tearful and requesting “anything” for 
pain control.   
BP= 150/97 by automated blood pressure cuff 
HR = 160 regular 
RR = 24 
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 Temp = 98.2 
O2 Saturation via pulse oximetry  = 99% on 100% O2 by non-rebreather mask.  
Urine is positive for blood, white cells, positive nitrites by dipstick, specific gravity= 
1.030. Urine output is about 100 ml over the last 30 minutes.    
CMO reports no bowel sound heard and severe tenderness on right CVA percussion. 
Patient refuses all other examination maneuvers. Under your real-time guidance, the 
CMO performs an abdominal exam on FE2. A pelvic exam is differed at this time due 
to the extreme pain and discomfort FE2 is experiencing and the inexperience of the 
CMO.   
 
Question 3. Given the previous circumstances surrounding the medical exam, what 
history and reported physical findings would you trust as accurate? 
A. Absent bowel sounds 
B. CVA tenderness 
C. Rebound tenderness 
D. Murphy’s sign 
E. Severe colicky flank pain 
F. “tinkling” bowel sounds  
G. Fever 
H. Pulsatile midline abdomen  
I. Abdominal tenderness 
J. Volume Status 
Using private communications with the CMO, you advise him that FE2 is experiencing 
an acute abdominal event and ask him to deploy the Ambulatory Medical Pack (AMP) 
and wait for medication orders.  The AMP contains many oral and IM medications 
which could potentially be prescribed for FE2. 
Question 4: What supportive medical treatment would you offer the FE2 at this time? 
A. ASA 325 mg PO 
B. Tylenol 325 mg PO 
C. Ibuprofen 400 mg PO 
D. Naprosyn 250 mg PO 
E. Prednisone 10 mg PO 
F. IV Ketorolac Tromethamine 30mg IV 
G. Phenergan 50 mg IM 
H. IV fluid 0.9NS at 500 ml/hr 
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 I. Morphine 0.05 to 0.1 mg/kg IM Q3-6h 
J. Meperidine 0.5 to 1.0 mg/kg IM Q3-4h 
K. Lorazepam 2 mg PO  
L. Foley catheter 
 
 
Due to the privacy maintained during the PMC, the Flight Director has not been able to 
hear or see any of the conversation between you and the crew.  The Flight Director 
asks you about this and you advise him that, at the moment a “mission impact” 
medical condition is being evaluated and an expedited return to Earth may need to be 
considered. The space shuttle left the ISS 30 days ago after completing a routine 
resupply mission, with the next shuttle launch to the ISS expected in 2 weeks to install 
more components of the ISS. The default emergency return vehicle is the Russian 
Soyuz, which is afforded a nominal landing opportunity in Kazakhstan only every 19 to 
21 hours.  FE2 is the Soyuz commander with the most experience in navigating the 
Soyuz during launch, docking, undocking and landing. The flight director informs you 
that we are only 6 hours away from when the Soyuz would need to undock from ISS to 
make the next Primary Landing Site (PLS) opportunity in Kazakhstan or Russia 
otherwise the next PLS opportunity will be in 25 hours from now.  You inform the Flight 
Director that FE2 was given 10 of Morphine IM 30 minutes ago by the CMO and 
therefore is probably not qualified to activate and fly the Soyuz. The Flight Director 
spends the next 30 minutes in an emergency conference with the rest of the flight 
control team at Mission Control and the ISS Commander, and subsequently orders the 
MCC prepare to abandon the ISS until told to stand down.  The flight director informs 
you that he will need to make a GO/NOGO deorbit decision in 3 hours and to advise 
the flight control team what resources you need to accomplish this. 
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 After a discussion with the BME, you advise the Flight Director that a more informed 
decision can be obtained by using the Health Research Facility (HRF) ISS ultrasound 
unit currently being flown in the laboratory module.  One hour later GC reports the 
HRF ultrasound team is in MCC and that the ultrasound system is ready for use.  
Using real time guidance from a sonographer on console in MCC, the CMO was able 
to obtain clinically useful images for evaluation by a radiologist who was also called 
into MCC.  The ultrasound images obtained real-time, rule out any gross vascular, 
hepatic, gastro-intestinal and ovarian pathology.  Of interest was a significant dilation 
of the right renal calyces and an echogenic mass in the proximal ureter measuring 4 to 
5mm.  Doppler images of the bladder showed classic left ureteral jets, indicating 
patency between the bladder and left kidney.  Unfortunately no jets were found on the 
right which is consistent with a right ureteral obstruction.  Although the patient is 
clearly obstructed, you cannot tell whether it is a “complete” obstruction without 
contrast.  The classic sign is a very delayed nephrogram.  Seeing a column of urine 
does not indicate degree of obstruction. Seeing a column of urine does not indicate 
degree of obstruction. FE2 is not taking fluid because of nausea and is still 
complaining of severe abdominal and flank pain. There are no other echogenic 
masses seen in the renal parenchyma or abdomen.  
Question 5. Based on the results of the diagnostic imaging what is this patient’s 
prognosis? 
A. No Problem – the patient should pass this stone easily without any 
complications 
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 B. Permanent obstruction requiring emergent lithotripic or surgical intervention 
is required to save the patients renal function.  
C. Acute Tubular Necrosis 
D. Acute Renal Failure 
E. Could pass the stone with a trial of therapy ( IV fluids, paincontrol) 
F. Patient is at high risk for pyelonephritis 
G. Not enough information at this time 
Three hours have passed since your initial discussion with the flight director and he 
has asked you to speak with him privately regarding the status of FE2.  You inform the 
flight director that you are very confident that FE2 is suffering from an acute right renal 
obstruction secondary to urolithiasis. You explain that this medical problem may not 
resolve on orbit, however, treatment has been started.  FE2 is not able to perform any 
mission related duties and will require 24 monitoring and medical support. 
Question 6. Based on the results of the diagnostic imaging you instruct the CMO to 
perform which of the following?  
A. Start a Morphine 2-5 mg IV q15min (limited by RR <16 bpm and systolic BP 
<100 mm Hg) prn for pain relief . 
B. Morphine 10 mg. IM q6h PRN 
C. IV NS TKVO  
D. IV NS 500 ml/hour 
E. Augmentin 500 mg X 2 stat then Q8H 
F. Ciprofloxacin 500mg  PO BID 
G. Amikacin/ceftriaxone  IV  
H. Vitals q1h 
I. Vitals q15min 
J. Vitals q5min 
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 K. Ketorolac/Tromethamine 30 mg IV initially,  followed by 15 mg IV q8h prn  
L. Ketorolac/Tromethamine 15 mg IM initially,  followed by 15 mg IM q8h prn 
You now feel that FE2 has an adequate pain control plan for the next 24 to 28 hours 
but unfortunately is now not able to “fly” the Soyuz under the influence of these 
medications.  NASA management has called the flight director for an update of the 
situation because the media is now covering this event on national TV. 
Question 7. The Flight Director asks you which of the following options you would 
medically consider is appropriate over the next 24 hours. 
A. Contingency deorbit to Continental United States within 3 hours with 1 
minute of 8-10 Gx exposure 
B. Nominal Soyuz deorbit to Kazakhstan or Russia in 6 hours with 3 minutes 
3.8 Gx exposure. 
C. Manage the problem on orbit as contingency deorbiting is dangerous 
D. Wait for the Space Shuttle to return in 14 days 
E. Miss the next PLS and re-evaluate in 12 hours. 
F. No recommendation is possible at this time 
You have discussed the results of the ultrasound with the experts in MCC, Medical 
Operations management and the Russian medical support team in Mission Control 
Moscow.  It is the consensus of these experts that the size of the obstructing kidney 
stone is small enough to attempt a “trial of therapy” consisting of IV fluids loads and 
aggressive pain management. Your recommendation to the Flight Director is to stand-
down from the plan to deorbit to the next PLS in Kazakhstan, however, a nominal 
Soyuz deorbit in 25 hours will be needed if FE2’s symptoms do not improve.  You 
advise him that we have no means of removing a small stone on orbit and the supply 
of pain control medications will not last greater than 32 hours. You also suggest that a 
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 contingency deorbit of 8 to 10 Gx exposure with knees above the head for a patient 
suffering from an acute renal obstruction may become intolerable to the patient. You 
also remind him that an emergency deorbit to other parts of the world may not be 
effective since there is no guarantee that the crew will be rescued by globally 
deployed military resources for as long as 24 hours after landing.   
The flight Director is reminded by CAPCOM that the commander (CDR) who is 
assisting the CMO is also the backup Soyuz pilot and that he will need to be released 
from patient care to prepare for the possibility of having to fly the Soyuz and prepare 
the ISS for abandonment since FE2 is incapacitated. The Flight Director orders the 
MCC to stand-down for a next PLS landing but to prepare for a PLS landing in 25 
hours when the opportunity occurs again.  CAPCOM instructs the CDR that he is 
released from medical duties unless a medical emergency is declared.  FE2 is stable 
with pain controlled with Morphine IM and IV fluids.   
Approximately 16 hours after the initial medical event you have become concerned 
about the lack of improvement in FE2 and the deterioration of her vitals signs.  The 
last physical exam conducted by the CMO under your guidance by video conference 
shows the following. 
On examination it is noticed that the patient is anxious, diaphoretic, pale and vomiting. 
Patient complains of chills and shakes with occasional rigors.  Her pain is about 9/10 
and it has been 5 hours since her last IM injection of morphine.  She states her pain 
has “moved” to be more into the pelvis and midline but continues to have and right 
CVA discomfort. She states that this is the worst pain she has ever experienced in her 
life.    
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 BP= 100/60 by automated blood pressure cuff 
HR = 175 regular 
RR = 24 
Temp = 103.4  
Approximately 250 mls of urine output over the last 6 hours  
O2 Saturation via pulse oximetry  = 99% on 100% O2 by non-rebreather mask.  
The urine is still positive for blood, white cells, nitrites and ketones by dipstick, Specific 
gravity = 1.0010 
CMO reports no bowel sound heard and severe pain on right CVA percussion. Patient 
refuses all other examination maneuvers. Urine samples are positive for blood, white 
cells, nitrates and ketones by dipstick.    
Question 8. Based on the physical exam information prescribe the flowing treatment 
for the non-physician CMO to provide:? 
A. Continue IV NS 500 ml/hour 
B. Augmentin (500 mg PO X 2 STAT then Q8H) 
C. IV Amikacin  (7.5 mg per kg Q12H) 
D. Ceftriaxone (100 mg/kg/day, up to 2 g/day IV, as a single daily dose) 
E. Ciprofloxacin (500 mg  PO BID) 
F. Phenergan (25 mg IV STAT) 
G. Phenergan (25 mg IM STAT) 
H. Repeat the ultrasound exam 
I. Inform flight director we are definitely going to need to deorbit for next PLS 
J. Wave off the current deorbit and reassess for next PLS 
 
You inform the flight director that the medical management team feels that deorbit to 
next PLS is the only option available now that the patient is showing signs of a 
complete right urinary obstruction with a likely diagnosis of pyelonephritis with possible 
urosepsis.  You understand that the presence of blood in the urine can cause false 
positive nitrites to be indicated on a urine dip stick but the clinical presentation is 
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 nonetheless very consistent with infection.   You prescribe double gram negative 
coverage consisting of Amikacin/ceftriaxone IV since urospesis is potentially fatal 
within hours.  The flight director instructs the flight control team to start procedures to 
deorbit to next PLS and prepare the ISS for abandonment.  
Approximately 6 hours prior to the undock and planned abandonment of the ISS( 18 
hours after the last PLS opportunity), FE2 reports a very sudden decrease in pain and 
becomes quite sleepy.  FE2 is requesting time to sleep and you suspect that she may 
have passed the stone and the narcotics may now be sedating FE2 in the absence of 
pain but you are also concerned that she is becoming obtunded secondary to a 
possible sepsis.  A second ultrasound was performed 30 minutes later and showing 
restoration of flow in the right ureter was confirmed by the large ureteral jets seen on 
the right side.  You ask the CMO to discontinue all narcotic pain medications because 
they are making FE2 excessively drowsy now that her pain has abated.  
You notify the Flight Director that FE2 no longer has an obstruction of her right kidney 
but there is still a possibility that she still may be suffering from serious urosepsis.  
You further suggest that a medical GO/NOGO decision for next PLS should be not 
canceled until you can confirm that FE2’s condition has definitely improved.  
During the next 4 hours you discontinue pain meds, but maintain IV hydration and 
NSAIDs and continue to prepare for deorbit. You advise the CMO not to perform any 
oral reentry fluid-loading countermeasures on FE2.  An adequate supply of IV 
analgesics and anti emetics are placed in the Soyuz for the deorbit to next PLS which 
will confine the crew of three in a very small capsule for up to 3 hours.  You guide the 
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 CMO though another physical exam using the videoconferencing system and the 
following information is obtained: 
On examination it is noticed that the patient is relaxed and in relatively good humor. 
Patient no longer has any complaints of chills, shakes or nausea.  Her pain is about 
1/10 and it has been 4 hours since her last IM injection of morphine.  She states her 
pain has all but gone but still has some very mild right CVA discomfort. She is very 
thirsty.     
BP= 120/75 by automated blood pressure cuff 
HR = 85 regular 
RR = 16 non-labored 
Temp = 99.6  
Approximately 1950 mls of urine output since her pain decreased.  
O2 Saturation via pulse oximetry  = 99% on 100% O2 by non-rebreather mask.  
CMO reports bowel sounds present and minimal pain on right CVA percussion. The 
urine is still positive for blood, white cells, mild nitrates and ketones by dipstick, 
Specific gravity = 1.0021.    
Question 9. Based on the recent physical exam and diagnostic imaging information 
you prescribe which of the flowing treatments for FE2? 
A. Continue IV NS 500 ml/hour 
B. Continue IV Amikacin/ceftriaxone  
C. Start Ciprofloxacin 500mg  PO BID 
D. Vitals q1h 
E. Vitals q15min 
F. Discontinue Oxygen  
G. Continue Ketorolac/Tromethamine 15 mg IM q8h prn  
H. Discontinue Ketorolac/Tromethamine 
I. Repeat the ultrasound exam 
J. Remove Foley catheter but strain urine for stones. 
K. Wave off the current deorbit and reassess for next PLS 
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 You inform the flight director that FE2 is improving and her last exam indicated that 
her infection is resolving due to the resolution of her kidney obstruction.  The next PLS 
deorbit is not indicated at this time, however you advise for the flight control team to 
consider future next PLS deorbits until the situation is completely resolved. The Flight 
Director orders that the flight control team stand down from next PLS but be ready to 
consider the next available deorbit which is 21 hours from now. 
FE2 was advised to increase fluid intakes and monitor her urine to keep it clear and 
very well diluted. She remained on orbit until nominal end of mission and had an 
uneventful landing at Kazakhstan. 
Question 10.)  After her mission, you advise FE2 that she? 
A. is disqualified from long duration spaceflight 
B. is disqualified from short duration spaceflight 
C. is potentially waiverable for short duration flight  
D. should receive Renal Stone Risk assessment 
E. should receive a CT – fine 2mm renal slices 
F. should receive a Nephro – tomogram 
G. should receive a Spiral CT with pyelogram phase,  
H. should receive a Metabolic stone work up 
I. no workup necessary since it was spaceflight which caused this 
The acute renal obstruction completely resolved and FE2 was returned to all mission 
duties except EVA because of the risk of dehydration for this activity.  FE2 retired from 
the space agency and is in the process of writing her memoirs about being an ISS 
crew member.  She has not had any repeat episodes of acute renal obstruction to 
date.  
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 The most sensitive preflight study for determining if stones exist is a non-contrast 
renal CT.  It is sensitive enough to show calculi forming on the papilla which is 
commonly referred to as “Randall’s plaque”.35  The use CT is becoming more frequent 
for ruling out the presence of pathological calcium in soft tissues such as coronary 
arteries.8,24,43  Unenhanced helical CT allows rapid and accurate determination of 
whether a stone is present anywhere in the urinary tract.1 This screening test requires 
no contrast medium and takes only 5 to 10 minutes of imaging time, making it cost 
effective. Future astronaut selection may need to employ this modality to help prevent 
incidents like this from occurring in space again.  
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ANSWERS / DISCUSSION 
Answer. J - All the above 
Question 1. Based on your limited knowledge at this time, your differential diagnosis 
should include which of the following potentially life-threatening causes? 
A. Aortic dissection 
B. Appendicitis 
C. Ruptured Ovarian Cyst 
D. Diverticulitis 
E. Ectopic pregnancy (2 months since launch) 
F. Renal Obstruction 
G. Acute Cholecystitis 
H. Gastritis 
I. Small Bowel Obstruction.  
J. All of the above 
All of the conditions posited in the question fit within the differential diagnosis of the 
presenting symptoms and must be considered. Each is potentially life-threatening and 
would be a disastrous oversight to miss.  Many of the entities in this list are treatable 
with the proper knowledge and equipment.  Aortic dissection is not commonly found in 
this age group of females and the possibility of an ectopic pregnancy 8 weeks after 
launch is obviously not a consideration in this scenario. Nonetheless, all of these 
diagnoses would fit within the differential of a left lower quadrant acute abdomen in a 
premenopausal female.  
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 Answer I – all the above 
Question 2. While driving to MCC in your car, you think of additional information that 
should be obtained from the medical record or directly from the patient. What 
characteristics in the family or past medical history raise concern with this case 
prompting a more detailed history? 
A. Family history of kidney stones  
B. Diet ( Russian’s diet is rich in meat, a source of uric acid, NaCl, etc) 
C. Preflight Stone Risk Profile 
D. Geographic, environmental conditions 
E. Family history of cholelithiasis  
F. Family history of  peptic ulcer 
G. A history of any diet supplements of Vitamins 
H. Recent or chronic medications 
I. All the above 
Human exposure to microgravity results in alterations in renal function, fluid 
redistribution, bone loss, and muscle atrophy, all of which contribute to an altered 
urinary milieu and the potential for renal stone formation during and immediately after 
flight. Since the early flights of Gemini it has been known that the unloading of bone in 
microgravity causes a commensurate hypercalcuria which seems to continue almost 
indefinitely during short and long duration missions. You recall the fact that renal 
stones have been found in 12 active US astronauts and many of these happened 
within 9 to 120 months post flight.33  The Russians have experienced multiple renal 
stone events with one actually happening during a mission almost causing an abort 
due to intractable symptoms.  The in-flight episode resolved spontaneously and the 
mission was completed.     
In-flight changes include decreased urine volume and increased urinary secretion of 
calcium, phosphate, potassium, and sodium. Microgravity possibly alters renal stone 
protein inhibitor excretion rates increasing the risk of crystallization. Increased 
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 concentration of urinary constituents may be caused by either low urine volume 
(dehydration, dry climates) or by increased urinary chemical excretion (hypercalcuria, 
hyperoxaluria, hyperuricosuria, cystinuria). Decreased urine solubility can be induced 
by an abnormal urine pH (uric acid and phosphate-containing calculi can be 
precipitated by acidic, and alkaline, urine respectively).  
Diet may play a significant role in the pathogenesis of kidney stones. High protein and 
salt intake increase the risk of calcium stone formation. High purine diets (meat, fish, 
chicken) lower urinary pH and cause increased excretion of uric acid. Vitamin B6 
deficiency leads to increased formation and excretion of oxalate. Dehydration, 
excessive vitamin C intake, calcium supplementation, and calcium containing antacids 
may also lead to stone formation.  
The reduced gravity environment combined with FE2’s poor oral intake of fluids 
causes you to suspect that she may have has very concentrated urine with possibly 
high concentrations of calcium which is promotes the growth microlithiasis.  Therefore, 
your presumptive diagnosis is acute renal obstruction secondary to a kidney stone 
formed while living in the ISS.   
A family history of nephrolithiasis may be useful in determining the etiology of this 
patient’s presentation.  Selection history and physical examination are quite extensive 
and most likely any significant family history would have been already know.  FE2 was 
cleared of any evidence of renal tubular acidosis, hyperparathyroidism, chonic urinary 
tract infections and hypercalcuria at selection. She had a negative Renal Stone Risk 
workup (ref) which unfortunately does not always identify all individuals who will 
eventually have idiopathic or stress induced nephrolithiasis.   
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 Question 3. Given the previous circumstances surrounding the medical exam, what 
history and reported physical findings would you trust as accurate? 
A. Absent bowel sounds 
B. CVA tenderness 
C. Rebound tenderness 
D. Murphy’s sign 
E. Severe colicky flank pain 
F. “tinkling” bowel sounds  
G. Fever 
H. Pulsatile midline abdomen  
I. Abdominal tenderness 
J. Volume status 
Each of the exam findings listed makes sense on Earth however pathophysiology in 
some organ systems (i.e. change of pain with position) is predictably altered in 
microgravity.  This medical emergency requires care to be provided by the CMO using 
step-by-step instructions from a capable physician at the Mission Control Center via 
two-way audio and video.  Some of these findings are changed or made useless by 
the conditions posited in the question. Ambient noise and inadequate CMO training 
are likely to make abnormal ausculatory bowel sound findings unreliable at best.  
There also is a normal 1- to 2-liter cephalad fluid shift from the legs (primarily the 
thighs) that takes place in the first 8 to 24 hours of space flight28 and remains until 
landing.  This shift in fluid towards the heart is paradoxically accompanied by about a 
5- to 7- mmHg decrease in central venous pressure (CVP)3 with no clinically 
significant changes in cardiac output.  The bedside examination of the jugular venous 
pressure (JVP) on Earth is a reliable indicator of right atrial pressure and helps 
determine volume status because the vena cava acts as a venous hydrostatic column 
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 of blood. Jugular venous distension is a normal response to space flight that persists 
throughout the mission and would not be helpful in determining changes in central 
volume status.  
Urgent urologic consultation is indicated when fever suggests infection or an 
obstructed kidney or intravenous pyelography shows a nonfunctioning kidney 
(completely obstructed ureter), a partially obstructed ureter in a patient with only one 
kidney, or urine extravasation.  The following table is useful in helping determine the 
nature and possible cause of abdominal pain.  
Table 1  Typical Presentations of Abdominal Pan 
Symptom Peptic ulcer Renal 
colic 
Biliary colic Appendiciti
s 
Gastroenterit
is 
Colicky pain No Yes Yes No Yes 
Localized 
pain 
Yes Yes Yes Yes No 
Fever No No No Yes Not frequent 
Diarrhea No No No Not 
frequent 
Yes 
Abdominal 
tenderness  
Yes No Not frequent Yes Not frequent 
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 Answer – F,H, I,L 
Question 4: What supportive medical treatment would you offer the FE2 at this time? 
A. ASA 325 mg PO 
B. Tylenol 325 mg PO 
C. Ibuprofen 400 mg PO 
D. Naprosyn 250 mg PO 
E. Prednisone 10 mg PO 
F. IV Ketorolac Tromethamine 30mg IV 
G. Phenergan 50 mg IM 
H. IV fluid 0.9NS at 500 ml/hr 
I. Morphine 10 mg Q6H PRN pain 
J. Meperidine 0.5 to 1.0 mg/kg IM Q3-4h 
K. Lorazepam 2 mg PO  
L. Foley Catheter 
All the treatments above are used to control inflammation or pain under many medical 
circumstances.  A premenopausal female with acute onset of debilitating 
abdominal/pelvic pain and tenderness presents a pain management problem given the 
wide differential diagnosis.  ASA is contraindicated in several of the diagnoses being 
considered and the patient has already taken ASA with little effect.  Tylenol alone with 
probably not be effective with this level of pain but could be considered for adjunctive 
pain control.   
The presumptive diagnosis is renal colic however an acute bowel obstruction may be 
further exacerbated with opiates.  Regardless, the first step in management of acute 
renal colic is to alleviate the patient's pain with analgesics, such as Morphine. Patients 
with nausea and vomiting who cannot tolerate oral rehydration and oral analgesics 
should receive IV fluids and analgesics. 
Nonsteroidal anti-inflammatory agents (NSAIDS), such as Ketorolac Tromethamine , 
may be considered in cases of uncontrolled renal colic. Oral NSAIDS may not be 
tolerated but decrease pain by reducing GFR and therefore urine output, almost 
immediately.  The use of ASA with NSAIDS in the face of a possible post obstructive 
nephropathy may increase nephrotoxicty.  
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 FE2 should be encouraged to force fluids (2 to 3 L/day) to dilute urine and encourage 
passage of the presumed stone. A Foley catheter is clearly indicated in this situation 
to monitor urine output.  Typically urine should be filtered through a strainer, stocking, 
or filter paper so a passed stone can be retained for evaluation; however this is not 
easily accomplished in microgravity. It is always important to be alert for infection or 
obstruction. Infection may occur with fever or white cells in urine, and obstruction may 
detected using ultrasound. Stones smaller than 5 mm usually pass spontaneously. 
Those between 5 and 10 mm have a 50% chance of passing spontaneously. Larger 
stones usually need to be removed surgically. Be aware that other causes of pain (eg, 
lumbosacral strain, dissection of the aorta, malingering) can masquerade as renal 
colic.  
Meperidine in this setting is not the first drug of choice for pain control due to its 
propensity to induce nausea and vomiting.  Lorazepam would have little effect on the 
pain and would only be advised if the patient need concurrent anxiolytics.     
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 Answer – C,D,E,F 
Question 5. Based on the results of the diagnostic imaging what is this patient’s 
prognosis? 
A. No Problem – the patient should pass this stone easily without any 
complications 
B. Permanent obstruction requiring emergent surgical intervention is required 
to save the patients renal function.  
C. Acute Tubular Necrosis 
D. Acute Renal Failure 
E. Could pass the stone with a trial of therapy ( IV fluids, paincontrol) 
F. Patient is at high risk for pyelonephritis 
 
The probability that a renal stone will pass spontaneously over a prolonged period of 
time ( usually 3 months or more) depends on the size of the stone. The likelihood of 
spontaneous passage is about 80% for stones smaller than 4 mm, 59% for stones 
between 4 and 6 mm, and 21% for stones larger than 6 mm.38  Stones smaller than 5 
mm may be initially managed with fluids and analgesics.  Hydronephrosis, which is 
commonly seen, is not an indication for immediate endoscopic, surgical or lithotripic 
intervention but should be followed closely. A urinary tract infection concurrent with 
an obstructed stone requires immediate removal because the risk of urosepsis and 
irreversible renal injury is exceedingly high.  The type of intervention chosen depends 
upon the size, location, and type of stone as well as the clinical features of the patient 
(eg, body habitus, infection).   
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 An upper ureteral stone is generally treated using extracorporeal shock wave 
lithotripsy (ESWL) with a greater than 90% stonefree rate. Stone removal using 
retrograde ureteroscopy is generally reserved for stones in which ESWL has failed to 
resolve, for cystine stones, or for distally located stones causing obstruction.  Stones 
located in the midureter are in close proximity to the pelvic bones which can absorb a 
significant amount of the energy of the ESWL shock wave.  Ureteroscopic stone 
removal is the preferred modality in these locations especially for stones larger than 
10 mm or when stents are required to relieve intractable pain or obstruction or to treat 
infection.38  
The management of the distal ureteral stone in FE2 is complicated by the 
environment of the ISS and the available resources.  Most certainly a trial of fluids 
and analgesia is prudent but the limited ability to return to Earth may cause you to be 
more conservative in your approach.  This patient can develop acute renal failure of 
her right kidney and most certainly acute tubular necrosis.  Acute pylonephritis in the 
setting of obstruction needs to be promptly treated in a hospital setting.  This patient 
has pyuria but no fever or sign of sepsis.  Clearly a failure of medical therapy on-orbit 
would incur a mission cost of several 100 million dollars if FE2 requires urological 
intervention on Earth. 
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 Answer – B,D,F,I,L 
Question 6. Based on the results of the diagnostic imaging you instruct the CMO to 
perform which of the following? 
A. Start a Morphine 2-5 mg IV q15min (limited by RR <16 bpm and systolic BP 
<100 mm Hg) prn for pain relief . 
B. Morphine 10 mg. IM q6h PRN 
C. IV NS TKVO  
D. IV NS 500 ml/hour  
E. Augmentin 500 mg X 2 stat then Q8H 
F. Ciprofloxacin 500mg  PO BID 
G. Amikacin/ceftriaxone  IV  
H. Vitals q1h 
I. Vitals q15min 
J. Vitals q5min 
K. Ketorolac Tromethamine 30 mg IV initially,  followed by 15 mg IV q8h prn  
L. Ketorolac/Tromethamine 15 mg IM initially,  followed by 15 mg IM q8h prn 
Terrestrial diagnosis of nephrolithiasis is usually based upon a intravenous pyelogram, 
unless the patient is allergic to contrast media or has substantial risk of a contrast-
induced renal failure.41  Renal ultrasound imaging is usually adequate for determining 
the presence of nephrolithiasis. Ureteral calculi, especially in the distal ureter, and 
stones smaller than 5 mm are not always observed on ultrasound.  
The role of supranormal hydration in the management of renal/ureteral colic is 
debatable however, hypovolemic patients need adequate restoration of circulating 
volume to prevent further exacerbation of a supersaturated urine environment. Typical 
workup of a patient suffering from renal colic includes a urinalysis, CBC, and 
electrolyte, BUN, creatinine, and serum calcium levels. Unfortunately, most of these 
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 are not available on orbit.  Urine cultures should be obtained because urinalysis alone 
may not be sufficient to exclude a urinary tract infection.  Obtaining a urine sample for 
post mission stone risk profile would be helpful; unfortunately there is no refrigeration 
capability on the ISS for urine sample storage.14  
If the patient has vomiting, dehydration, fever, signs of infection, or a complete 
obstruction, de-orbit for hospitalization in indicated and urgent on-orbit treatment 
should be initiated.  
The cornerstone of management of renal/ureteral colic is analgesia and can be 
accomplished most effectively with parenteral narcotics or nonsteroidal anti-
inflammatory drugs (NSAIDs). Morphine sulfate is the renal colic narcotic analgesic 
drug of choice for parenteral and intramuscular use however, its use may be require 
you to address nausea, emesis, and urinary retention.   
Ketorolac tromethamine is the only NSAID approved for parenteral use for renal colic 
in the United States, and it is often effective when used for renal colic with an onset of 
action being clinically evident within 10 min.  Antiemetic agents such as 
metoclopramide HCl, and prochlorperazine may also be added as needed. It should 
be understood that promethazine may impair the passage of a stone due to its 
potential side effect of urinary retention.   
A urinary tract infection behind an obstructing stone is an emergency and healthy 
adults can develop urosepsis and die within 4 hours.  Terrestrial medical standards 
require that stenting or percutaneous drainage be performed immediately.   Attempts 
to remove a stone should not be performed if an infectious process is ongoing.   
Urosepsis, once started, will not resolve without renal drainage.  Since these 
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 procedures aren’t available in space, it is probably prudent to start all patients who 
present with renal colic on oral antibiotics.  If tolerated, oral antibiotics in this setting 
may be appropriate and Ciprofloxacin provides good gram negative coverage.  
Augmentin has Clavulinate which in the face of renal obstruction may complicate its 
pharmacodynamics.   Intravenous antibiotics are not indicated at this time and the 
delivery of many intravenous fluids and medications concurrently by a non-physician 
CMO in microgravity will be difficult.   
Although not commonly used for this illness on Earth, prednisone may be added to 
help reduce ureteral inflammation and calcium channel blockers, such as nifedipine, 
also relaxes ureteral smooth muscle. Amelioration of both ureteral inflammation and 
ureteral muscle tone appears to facilitate stone passage. More recently, the use of 
selective alpha blockers such as Tamsulosin HCL (Flomax®) or Alfuzosin HCL 
(Uroxatral®) has become standard of care for increasing the passage of stones, 
however, these drugs are not currently manifested on the ISS.  
This patient is stable and IM injections of an NSAID and analgesia are appropriate.  
Intravenous fluids should be given aggressively.  Should FE2 pass the stone a 
significant post obstructive dieresis may occur with a dramatic increase in urine flow 
and possible electrolyte loss via the affected kidney. 
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 Answer: E 
Question 7. The Flight Director asks you which of the following options you would 
medically consider is appropriate over the next 24 hours. 
A. Contingency deorbit to Continental United States within 3 hours with 1 
minute of 8-10 Gx exposure 
B. Nominal Soyuz deorbit to Kazakhstan or Russia in 6 hours with 3 minutes 
3.8 Gx exposure. 
C. Manage the problem on orbit as contingency deorbiting is dangerous 
D. Wait for the Space Shuttle to return in 14 days 
E. Miss the next PLS and re-evaluate in 12 hours. 
F. No recommendation is possible at this time 
You recommend against a contingency deorbit to the continental United States due to 
the risks of this off nominal event to the other crewmembers, as well as the unknown 
effect of FE2 suffering from renal colic during an exposure to +8 Gx for at least one 
minute. The renal colic of FE2 is still presently uncontrolled, and she is the only 
crewmember who is the most qualified to fly the Soyuz.  Maintaining adequate pain 
control of a crew member during a Soyuz reentry would be very challenging to a non-
physician CMO, and the very confined space would prevent the CMO from monitoring 
or managing the patient.  Your recommendation to the Flight Director is for a nominal 
Soyuz deorbit from the ISS to Kazakhstan since a contingency deorbit of 8 to 10 Gx 
exposure with knees above the head for a patient suffering from renal colic may be 
extremely uncomfortable. Nominal landings to Earth using the Soyuz are only 
supported at Kazakhstan because of limitations in its navigational software.  It could 
take more than 24 hours for a US military recovery crew to reach all other contingency 
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 landing sites throughout the world which may not be acceptable for patients suffering 
from nephrolithiasis and possible gram negative sepsis. 
Answer: A,C,F,I,J,K,M  
Question 8. Based on the physical exam information prescribe the flowing treatment 
for the CMO to provide:?  
A. Continue IV NS 500 ml/hour 
B. Augmentin 500 mg PO X 2 STAT then Q8H 
C. IV Amikacin/ceftriaxone  
D. Start Ciprofloxacin 500mg  PO BID 
E. Vitals q1h 
F. Vitals q15min 
G. Vitals q5min 
H. Discontinue Oxygen  
I. Continue Ketorolac/Tromethamine 15 mg IM q8h prn  
J. Repeat the ultrasound exam 
K. Use a strainer to “catch” any stones 
L. Wave off the current deorbit and reassess for next PLS 
M. Inform flight director we are definitely going to need to deorbit for next PLS 
FE2 is most likely suffering urosepsis until proven otherwise and prompt antibiotic 
treatment in required.  Phenergan should be given to help control the nausea and 
vomiting, however, the Flight Surgeon is aware of the potential for precipitation of 
Ketorolac Tromethamine and Phenergan in the same IV.  FE2 is receiving regular 
doses of intravenous Ketorolac/Tromethamine and therefore ASA is not indicated. 
Coadministration with aspirin increases the risk of inducing serious gastrointestinal 
NSAID-related side effects and probenecid may increase the renal toxicity of NSAIDs 
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 therefore Augmentin should be avoided since the FE2 already took ASA earlier. 
Ciprofloxacin has been shown to be very effective in treating complicated urinary tract 
infections and uncomplicated acute pylonephritis.42  Amikacin/ceftriaxone could be 
administered if FE2 cannot ingest oral antibiotics, however, managing several IV 
medications at the same time on the ISS is difficult for the CMO to administer and 
Flight Surgeon to monitor. Nonetheless ,given the potential for rapid deterioration of 
FE2’s vitals in such a hazardous environment, an immediate dose of IV 
Amikacin/ceftriaxone is indicated even though Amikacin induced nephrotoxicity and 
ototoxicity are potential complications .34  
 
 
Answer: A,B,C,D,F,G,K 
Question 9. Based on the recent physical exam and diagnostic imaging information 
you prescribe which of the flowing treatments for FE2? 
A. Continue IV NS 500 ml/hour 
B. Continue IV Amikacin/ceftriaxone  
C. Start Ciprofloxacin 500mg  PO BID 
D. Vitals q1h 
E. Vitals q15min 
F. Discontinue Oxygen  
G. Continue Ketorolac/Tromethamine 15 mg IM q8h prn  
H. Discontinue Ketorolac/Tromethamine 
I. Repeat the ultrasound exam 
J. Remove Foley catheter but strain urine for stones. 
K. Wave off the current deorbit and reassess for next PLS 
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FE2 should be encouraged to drink fluids PO and IV normal saline should be 
continued until FE2 can tolerate PO fluids.  IV antibiotics are appropriate for at least 
the next 24 hours given her previously septic presentation.  Starting a course of PO 
Ciprofloxacin now is appropriate since her IV antibiotics may get discontinued later.  
FE2 is stable and vitals q1h is appropriate. IM NSAIDS will be helpful in controlling the 
inflammatory response to her obstruction and can be discontinued in 24 hours.  A 
repeat ultrasound exam in 12 to 24 hours is advised to confirm bilateral urethral jets 
and a resolution of the calyceal dilation.  Next PLS should be waived given the 
improvement in FE2’s condition.
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 Question 10.)  After her mission, you advise FE2 that she? 
A. is disqualified from long duration spaceflight 
B. is disqualified from short duration spaceflight 
C. is potentially waiverable for short duration flight  
D. should receive Renal Stone Risk assessment 
E. should receive a CT – fine renal slices (2mm) 
F. should receive a Nephro – tomogram 
G. should receive a Spiral CT with pyelogram phase,  
H. should receive a Metabolic stone work up 
I. no workup necessary since it was spaceflight which caused this 
 
You advise the patient that the minimally invasive modalities for stone removal are 
generally successful in removing calculi. The usually quoted recurrence rate for 
urinary calculi on Earth is 50% within 5 years and 70% or higher within 10 years.  
Metabolic evaluation and treatment are indicated for patients at greater risk for 
recurrence, including those who present with multiple stones, those who have a 
history of previous stone formation, and those who present with stones at a younger 
age, however, this is not the case for FE2. The most important aspect of medical 
therapy is maintaining an increased fluid intake and high urinary volume. Without an 
adequate urinary volume, no amount of medical or dietary therapy is likely to be 
successful in preventing nephrolithiasis. Increasing fluid intake and dietary moderation 
can cut the stone recurrence rate by 60%. This phenomenon is known as the “stone 
clinic effect”. FE2 should be counseled to seek immediate medical attention if he or 
she experiences flank or abdominal pain or notes visible blood in the urine.  
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 Of significance is the fact that spaceflight alone may be the only risk factor responsible 
for this case of nephrolithiasis. During a long duration mission in space, calcium 
excretion (both urinary and fecal) is increased when compared to measurements 
taken before flight, 17 which results resulted in a net loss of calcium from the body 
causing . This is a great concern for bone loss and also elevated urinary calcium 
which can increase the risk of forming kidney stones47.  The Multilateral Space 
Medicine Board has disqualified FE2 from further ISS missions. 
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Discussion 
Renal and ureteral stones are a common problem and recent studies establish the 
occurrence of kidney stone disease has increased in many industrialized countries40. 
Patients typically present with the classic symptoms of renal colic and hematuria, 
however other presentations can be asymptomatic or have atypical symptoms such as 
vague abdominal pain, acute abdominal pain, nausea, difficulty urinating, penile pain, 
or even testicular pain. Nephrolithiasis is a relatively common problem and 
approximately 12 percent of men and 5 percent of women will have at least one 
symptomatic stone by the age of 70.16 The National Health and Nutritional 
Examination Survey reports that the prevalence of nephrolithiasis is increasing in the 
United States from 3.8 percent in the period 1976 to 1980 to 5.2 percent in the years 
1988 to 1994.40  Of patients with nephrolithiasis, eighty percent form stones which are 
composed primarily of calcium oxalate or, less often, calcium phosphate.6,16  The 
incidence of nephrolithiasis increases with age, and is higher in men , and in 
Caucasians39 with Hispanics and Asians being at an intermediate risk. It has been 
estimated that 7 to 10 of every 1,000 hospital admissions are due to nephrolithiasis.22  
Nephrolithiasis is most likely to occur when one or more factors contribute to 
supersaturation of the urine, the formation of calcium crystals, and their subsequent 
aggregation into an overt stone. Urine supersaturation can be increased by 
dehydration, hyperfiltration (too much calcium delivered), inadequate reabsorption in 
the tubules or over secretion of  oxalate, phosphate, cystine or uric acid.  
Asymptomatic subjects can excrete tiny crystal nuclei; however, this process is 
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 accelerated in nephrolithiasis prone patients who tend to excrete larger crystal 
aggregates and are more likely to have calcium oxalate crystals in the urine.36 Most 
certainly many of these risk factors can occur in space flight.11,12,25,31,46-49 A significant 
factor which contributes to the formation of certain stones is the urine pH. Most 
subjects excrete acidic urine throughout the day which promotes the precipitation of 
uric acid and can increase the risk for formation of calcium stones. Conversely, 
calcium phosphate stones precipitate in relatively alkaline urine, and calcium oxalate 
stones are not pH-dependent. 
It is unclear how crystals which have formed in the renal tubules eventually become a 
stone, rather than being washed away by the high rate of urine flow. One hypothesis is 
that crystal aggregates become large enough to anchor at the end of the collecting 
ducts and then increase in size over time.2,20,21,44This renal tubule crystal anchoring is 
thought to occur at sites of epithelial cell damage by binding to hyaluronan2,44 which is 
induced by the crystals themselves23,26. Another hypothesis supports the formation of 
a crystal nidus by nanobacteria, a class of atypical bacteria commonly found in kidney 
stones which is independent of stone composition18,19. In a study by Ciftcioglu et al5 of 
72 consecutive kidney stones, 97 percent tested positive for nanobacteria. 
In the absence of gravity, such as space flight, a rapid loss of bone mineral and 
osteopenia occurs through a mechanism which not completely understood.27,29,45   The  
unloading of the skeleton in microgravity may result from increased bone resorption, 
decreased bone formation, or both, however the analysis of bone from animals during 
space flight has not yielded consistent results.  There have been fewer studies of the 
effects of weightlessness on human bone metabolism because of the inherent 
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 difficulties in procuring bone biopsies from astronauts while in orbit.  Most bone biopsy 
studies have focused on immobilized patients such as those with spinal cord injury or 
normal subjects undergoing prolonged bed rest.32 More recently, the availability of 
biochemical assays for assessing bone resorption and formation activities has been 
used in assessing the skeletal response to both simulated weightlessness10 and long 
duration space flight.4,7  
This microgravity induced loss of bone calcium and phosphorus could promote the 
formation of nephrolithiasis, in part by causing secondary hypercalciuria and 
hyperphosphaturia.30,31 Pak et al31 analyzed 24-h urine samples for stone-forming risk 
factors in 104 male applicants before the final selection into the astronaut corps. Of 
interest was abnormal supersaturation of urine with calcium oxalate in 25.0% of 
applicants, brushite in 36.5%, and monosodium urate in 66.3% of applicants which 
predisposes them to nephrolithiasis from precipitation of calcium salts. The  
supersaturated urine was secondary to both "metabolic" and environmental factors. 
Metabolic factors included hypercalciuria in 11.5%,  hyperoxaluria in 2.9%, 
hyperuricosuria in 18.3% and hypocitraturia in 5.8% of applicant. Environmental 
factors included low urine volume of less than 2 L.d-1 in 84.6%, high urinary 
phosphate in 24.4%, and high urinary sodium in 10.6% of applicants. Pak et al31 found 
that the majority nephrolithiasis risk factors among astronaut applicants were 
environmental.  
Hwang et al15 studied the effect of prolonged bedrest of risk factors for nephrolithiasis.  
The crystallization of calcium salts was examined in eight normal subjects during 5 
weeks of bedrest. The mean urinary calcium excretion increased in the first week from 
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 5.68 to approximately 7.50 mmol/day and remained elevated thereafter. Mean urinary 
phosphorus excretion increased by the second week from 2.70 to approximately 30.6 
mmol/day and remained elevated. Urinary sodium, magnesium and uric acid excretion 
increased slightly and pH, oxalate, and citrate remained relatively unchanged. 
Nonetheless, urinary saturation of calcium phosphate, calcium oxalate, and 
monosodium urate increased significantly during bedrest. The inhibitor activity against 
nucleation of brushite and calcium oxalate was not increased by bedrest, therefore 
propensity for the crystallization of stone-forming calcium salts is enhanced by 
bedrest.  This suggests that gravitational unloading of the musculo-skeletal system in 
microgravity may confer increased risk for the formation of calcium-containing renal 
stones. 
Whitson et al examined 24 hr urine samples from 365 astronauts pre and post flight 
from4 to 17 day Shuttle missions.49 They found that urinary supersaturation levels of 
stone forming salts were reduced when urine volumes exceeded 2 liters per day. Of 
interest is the need for daily exercise countermeasures and the increase risk for 
calcium oxalate and uric acid stone formation with exercise which is not currently 
followed with fluid compensation.37 Another interesting potential risk for stone 
formation is during 6 to 8 hr Extravehicular Activities  (EVA) where dehydration is 
possible since fluid compensation is usually less than 2 liters.  
(add a small blurb about sepsis in space leo versus mars… refer to white paper9 
 
Note From the Authors: 
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 This case was presented to acquaint the reader with the tremendous challenges that 
face the flight surgeon when supporting a space mission.  The limited crew training 
time, medical hardware, and drugs manifested to deal with the previous medical event 
predicate that aggressive primary and secondary prevention strategies need to be 
developed to protect a 40-billion-dollar asset like the International Space Station.  
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